Publication
Europe steps up its fight against fraud
European watchdogs have long been focusing on enforcement against corporate crime with a great focus on anti-corruption, economic sanctions and money laundering.
Global | Publication | May 2017
Treaty/Act: CETA/Bill C-30 (An Act to implement the Comprehensive Economic and Trade Agreement between Canada and the European Union and its Member States and to provide for certain other measures)
Date: May 11, 2017 – Bill C-30 passes third reading in Senate
The overhaul to Canada’s pharmaceutical patent regime is nearly here. On May 11, 2017, the Canadian Senate passed Bill C-30 (the act intended to implement CETA into Canadian law) without amendment, the final major stage of the legislative process. Bill C-30 will become law once it receives royal assent, a formality.
As we reported, CETA and Bill C-30 provide key reforms to the Patent Act affecting the pharmaceutical industry, including:
We anticipate the details to be published shortly.
Are you CETA ready? Contact Norton Rose Fulbright with all your CETA questions.
Bill C-30, Third Reading (House of Commons)
Text of the final Comprehensive Economic and Trade Agreement
Publication
European watchdogs have long been focusing on enforcement against corporate crime with a great focus on anti-corruption, economic sanctions and money laundering.
Publication
The Digital Markets, Competition and Consumers Act (DMCC Act) received Royal Assent on 24 May 2024 and is generally expected to come into force in autumn this year.
Publication
Head of Legal Operations, Stephanie Hamon, will be joining the panel discussion on "Simplifying Legal Tech Adoption and Implementation" at the Legal Tech Talk conference on June 13th (3:30 - 4:15 PM).
Subscribe and stay up to date with the latest legal news, information and events . . .
© Norton Rose Fulbright LLP 2023